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A B S T R A C T
Neospora caninum is one of the main causes of abortion in cattle, and recent studies have highlighted its re-
levance as an abortifacient in small ruminants. Vaccines or drugs for the control of neosporosis are lacking.
Bumped kinase inhibitors (BKIs), which are ATP-competitive inhibitors of calcium dependent protein kinase 1
(CDPK1), were shown to be highly efficacious against several apicomplexan parasites in vitro and in laboratory
animal models. We here present the pharmacokinetics, safety and efficacy of BKI-1553 in pregnant ewes and
foetuses using a pregnant sheep model of N. caninum infection. BKI-1553 showed exposure in pregnant ewes
with trough concentrations of approximately 4 μM, and of 1 μM in foetuses. Subcutaneous BKI-1553 adminis-
tration increased rectal temperatures shortly after treatment, and resulted in dermal nodules triggering a slight
monocytosis after repeated doses at short intervals. BKI-1553 treatment decreased fever in infected pregnant
ewes already after two applications, resulted in a 37–50% reduction in foetal mortality, and modulated immune
responses; IFNγ levels were increased early after infection and IgG levels were reduced subsequently. N. caninum
was abundantly found in placental tissues; however, parasite detection in foetal brain tissue decreased from 94%
in the infected/untreated group to 69–71% in the treated groups. In summary, BKI-1553 confers partial pro-
tection against abortion in a ruminant experimental model of N. caninum infection during pregnancy. In addi-
tion, reduced parasite detection, parasite load and lesions in foetal brains were observed.
1. Introduction
Neospora caninum (Apicomplexa: Eimeriina: Sarcocystidae) is an
obligate intracellular parasite, known to be one of the most important
infectious causes of abortion in cattle worldwide (Dubey and Schares,
2011; Dubey et al., 2017). Since its discovery, N. caninum has been
identified in various species of livestock, including cattle, sheep, goats,
horses and deer (Dubey et al., 2007). Cattle can become infected by
horizontal transmission via the ingestion of oocysts, or by vertical
transmission (i.e., transplacentally) as a result of either a primary
infection of the dam by oocysts (exogenous transplacental transmission)
or recrudescence of a chronic infection (endogenous transplacental
transmission) during pregnancy, with different clinical and epidemio-
logical consequences (Williams et al., 2009).
The clinical and economic importance of neosporosis in small ru-
minants has historically been considered much less relevant compared
to infection by Toxoplasma gondii, which is one of the most common
causative agents of abortion in sheep and goats (Dubey, 2009). How-
ever, recent evidence suggests that N. caninum is also an important
abortifacient in small ruminants (Moreno et al., 2012) and may even be
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the main cause of reproductive losses in some flocks (West et al., 2006;
González-Warleta et al., 2014). Experimental infections in pregnant
sheep (McAllister et al., 1996; Buxton et al., 1998; Weston et al., 2009;
Arranz-Solís et al., 2015) have shown that they are highly susceptible,
and as in cattle, abortion and vertical transmission are the main con-
sequences of infection.
Many control measures have been proposed to reduce N. caninum
infection in cattle, including embryo transfer, artificial insemination of
seropositive dams, culling of infected animals and replacement by
healthy heifers, drug treatment and vaccination (Dubey et al., 2007).
The latter two options have been identified as economically viable,
provided suitable targets and efficacious drugs can be made available
(Häsler et al., 2006a, b). Although experimental studies have revealed
potent effects of several drugs in vitro and in laboratory animal models
(Müller and Hemphill, 2011; Hemphill et al., 2016), only triazinon
derivatives, such as ponazuril (Kritzner et al., 2002) and toltrazuril
(Haerdi et al., 2006; Syed-Hussain et al., 2015), and the polyether io-
nophore antibiotic monensin (Vanleeuwen et al., 2011) have been
tested in ruminants experimentally infected with N. caninum, but results
remained ambiguous. To date, pregnant ruminant models of neos-
porosis have not been used for assessments of drug efficacy against N.
caninum infection and vertical transmission.
Anti-parasitic drug development based on targeting kinase enzymes
is a well-established approach (Rotella, 2012). Calcium dependent
protein kinase 1 (CDPK1) represents a promising drug target, as CDPK1
is encoded by the apicoplast DNA, and is thus absent from mammalian
hosts (Lourido et al., 2010; Murphy et al., 2010; Ojo et al., 2010).
CDPK1 activity is essential for microneme secretion, host cell invasion,
and egress of T. gondii (Kieschnick et al., 2001; Lourido et al., 2010) and
can be effectively targeted by a class of ATP-competitive compounds,
collectively named bumped kinase inhibitors (BKIs).
BKIs have a broad-spectrum activity that affects many apicom-
plexan parasites (Van Voorhis et al., 2017). BKI-1294, BKI-1517 and
BKI-1553 were all effective against N. caninum in vitro and strongly
interfered with transplacental transmission in a pregnant mouse model
of neosporosis (Ojo et al., 2014; Winzer et al., 2015; Müller et al.,
2017a). BKI-1553 has been developed based on a variant on the
naphthalinyl-pyrazolopyrimidine scaffold of BKI-1294. BKI-1553 is
highly efficacious against T. gondii in vitro. It exhibits a low human
ether-a-go-go-related gene (hERG) ion channel inhibition, excellent
systemic exposure, crosses the blood-brain barrier in mice when ad-
ministered orally, and BKI-1553 treatment lead to reduced parasite
burden in the brain, lungs and liver of T. gondii infected mice (Vidadala
et al., 2016). We here report on the safety and efficacy of BKI-1553
treatment in pregnant sheep experimentally infected with N. caninum
tachyzoites at mid-gestation, drug levels in foetuses, and its impact on
vertical transmission.
2. Materials and methods
2.1. Ethics statement
All protocols involving animals were approved by the Animal
Welfare Committee of the Community of Madrid, Spain, following
proceedings described in Spanish and EU legislation (PROEX 166/14
-experiment 1- and PROEX 064/15 -experiment 2-, Law 32/2007, R.D.
53/2013, and Council Directive, 2010/63/EU). All animals used in this
study were handled in strict accordance with good clinical practices,
and all efforts were made to minimize suffering.
2.2. Experiment 1: pharmacokinetics, safety and efficacy of BKI-1553 in a
pregnant sheep model of neosporosis
2.2.1. Animals and experimental design
Fifty-four pure Rasa Aragonesa breed female lambs aged 3 months
were selected from a commercial flock. All animals were seronegative
for T. gondii, N. caninum, Border disease virus (BDV), Schmallenberg
virus (SBV), Coxiella burnetii and Chlamydia abortus as determined by
enzyme linked immunosorbent assay (ELISA). Animals were main-
tained in isolation in Zaragoza University (Spain) facilities until 12
months of age. They were oestrus-synchronized and mated with pure-
breed Rasa Aragonesa tups for 2 days, after which the rams were re-
moved from the ewes. Pregnancy and foetal viability were confirmed by
ultrasound scanning (US) on day 40 post-mating, and thirty-seven
pregnant sheep were selected for the experiment. Pregnant ewes
(n= 37) were randomly distributed into six experimental groups (see
Table 1) and housed at the Clinical Veterinary Hospital facilities
(Complutense University of Madrid, Spain). Twenty-four ewes were
allocated into groups 1 (G1; n=8), 3 (G3; n= 8) and 5 (G5; n=8),
which were inoculated intravenously with 106 tachyzoites of the bovine
isolate Nc-Spain7 (Regidor-Cerrillo et al., 2008) at day 90 of gestation
(dg). The thirteen remaining pregnant ewes were allocated to groups 2
(G2; n=5), 4 (G4; n= 5) and 6 (G6; n=3), which received an in-
travenous inoculum of phosphate-buffered saline (PBS) at 90 dg.
BKI-1553 was synthesized by Sundia Inc. (Shijiazhuang, China) and
further purified in the Department of Chemistry of the University of
Washington. The drug formulation was prepared by dissolving the
compound in 70% Tween 80 (Sigma-Aldrich, Madrid, Spain) and 30%
Ethanol 96° (Panreac, Barcelona, Spain) by heating at 60 °C and shaking
for 3 h at a final concentration of 69mg/mL. Starting at 48 h post-in-
fection, BKI-1553 was administered subcutaneously to G1 (1st dose:
35mg/kg bodyweight, 2nd dose: 10mg/kg bodyweight a week later)
and G3 (10mg/kg bodyweight, 7 doses every other day). G2 and G4,
which represented the corresponding non-infected treatment controls,
received the same doses as G1 and G3, respectively. Ewes from G1 and
G2 groups were dosed in their armpits with 13.12 ± 0.70mL for the
1st dose and 8.37 ± 0.93mL for the 2nd dose. Ewes from groups G3
and G4 were dosed in their armpits and inguinal regions with
Table 1
Experimental design.
Group Number of pregnant ewes Number of foetuses/lambs Inoculum (i.v.) Treatment (s.c.)
G1 8 14 Nc-Spain7
106 tachyzoites
BKI-1553, 1st dose: 35mg/kg bodyweight; a week later, a 2nd dose at 10mg/kg bodyweight
G2 5 7 PBS BKI-1553, 1st dose: 35mg/kg bodyweight; a week later, a 2nd dose at 10mg/kg bodyweight
G3 8 13 Nc-Spain7
106 tachyzoites
BKI-1553, 7 doses at 10mg/kg bodyweight every other day
G4 5 9 PBS BKI-1553, 7 doses at 10mg/kg bodyweight every other day
G5 8 13 Nc-Spain7
106 tachyzoites
None
G6 3 5 PBS None
i.v.: intravenous route.
s.c.: subcutaneous route.
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8.37 ± 0.20mL per dose. Ewes from the non-infected groups G2 and
G4 were culled around the time when abortion occurred in the re-
spective Neospora-infected groups G1 and G3, providing a negative
control for further analyses (see below). Ewes from G6 (non-infected,
no drug) were kept alive until the end of the experiment.
2.2.2. Parasites
Tachyzoites of the Nc-Spain7 isolate were routinely maintained in
cultured MARC-145 cells as described previously (Regidor-Cerrillo
et al., 2010). For the in vivo challenge, tachyzoites (passage 14) were
recovered from culture flasks when they were still largely intracellular
(> 80% of undisrupted parasitophorous vacuoles), and infected cells
were repeatedly passed through a 25-gauge needle at 4 °C. Tachyzoite
numbers were determined by Trypan blue exclusion followed by
counting in a Neubauer chamber, and parasites were resuspended in
PBS at the required dose of 106 tachyzoites in a final volume of 1mL.
Infection of ewes was carried out within 30min of harvesting the
parasites from cell culture.
2.2.3. Clinical monitoring
Pregnant ewes were observed daily throughout the entire experi-
mental period. Foetal viability was assessed by US monitoring of foetal
heartbeat and movements once a week during the first 14 days post-
infection (pi) and then twice weekly until detection of foetal death.
Rectal temperatures were recorded daily from day 0 until 14 days pi
and then weekly. The physiological range for rectal temperatures in
sheep was obtained from Ramos-Antón and Ferrer-Mayayo (2007), and
rectal temperatures above 40 °C were considered hyperthermic. Skin
lesions after subcutaneous BKI-1553 administration were recorded
daily until their resolution.
When foetal death occurred, or immediately after parturition, dams
and lambs were first sedated with xylazine (Rompun, Bayer, Mannhein,
Germany) and then euthanized by an intravenous overdose of embu-
tramide and mebezonium iodide (T61, Intervet, Salamanca, Spain). In
G2 and G4, at least one ewe was culled for each of the three ewes that
aborted in G1 and G3 as close as possible to the average day of abortion.
Animals from G6 were examined by US every two weeks. Lambs were
clinically inspected and weighed immediately after birth and then eu-
thanized.
2.2.4. Collection of blood samples
Blood samples to evaluate peripheral immune responses were col-
lected prior to infection and then weekly by jugular venipuncture into
5mL vacutainer tubes (Becton Dickinson and Company, Plymouth, UK)
with and without lithium heparin as anticoagulant. In addition, hae-
matological and biochemical parameters before (day 0 pi) and after
treatment (13 days pi for G1, G2, G5 and G6, and 18 days pi for G3 and
G4) were assessed in blood samples collected into 10mL vacutainer
tubes (Becton Dickinson and Company, Plymouth, UK), with ethyle-
nediaminetetraacetic acid (EDTA) as anticoagulant and into 5mL va-
cutainer tubes (Becton Dickinson and Company, Plymouth, UK) without
anticoagulant. Tubes without anticoagulant were allowed to clot and
were centrifuged to obtain serum samples that were stored at −80 °C
until analysis.
To determine BKI-1553 exposure, blood samples from the treated
groups G1-G4 were collected at multiple time points by jugular veni-
puncture into 2mL tubes (Aquisel, Barcelona, Spain) containing lithium
heparin. From G1 and G2, blood was collected prior to BKI-1553 ad-
ministration, after the 35mg/kg bodyweight dose at 12 h, 48 h and 7
days, and after the 10mg/kg bodyweight dose at 12 and 48 h and 4, 5,
6, 7, 10, 14 and 21 days. From G3 and G4, blood samples were collected
prior to BKI-1553 administration, 12 and 48 h after the first and second
doses, 48 h after the fourth and sixth doses and finally, 12 and 48 h and
4, 5, 6, 7, 10, 14 and 21 days after the seventh dose. Heparinised blood
samples were centrifuged at 805× g for 30min at 4 °C, and plasma
samples were stored at−20 °C until analysis by liquid chromatography
tandem mass spectrometry (LCMS/MS).
Precolostral serum was collected from lambs and maintained at
−80 °C for subsequent serological analysis. To prevent any transmis-
sion of colostral antibodies from dams, lambs were separated from their
mothers immediately after birth, sampled for blood and euthanized.
2.2.5. Post-mortem collection of tissue and body fluid samples
Six randomly selected placentomes or cotyledons from aborted/
euthanized dams and dams that gave birth, respectively, were re-
covered from each placenta, transversally cut into 2–3mm-thick slices,
and fixed in 10% formalin for histopathological examination, whereas
remaining tissues from these placentomes/cotyledons were stored at
−80 °C for further DNA extraction. Foetal brains were stored at−80 °C
for DNA extraction and fixed in 10% formalin for histopathological
examination. Foetal thoracic and abdominal fluids were also collected
from foetuses and maintained at −80 °C for serology.
2.2.6. BKI-1553 pharmacokinetics
BKI-1553 was extracted from the plasma samples using acetonitrile/
0.1% formic acid with an internal standard. A standard curve was
prepared for comparison and quantification. BKI-1553 was quantified
by analysis on a 6460 series triple quadrupole LC-MS/MS (Agilent,
Santa Clara, CA). For both doses in groups G1 and G2, and for the first
and seventh doses in groups G3 and G4, phamacokinetic (PK), calcu-
lations of maximum concentration (Cmax), and area-under-the-curve
(AUC) were determined using Pharsight Phoenix WinNonlin software
(Certara, St. Louis, MO).
2.2.7. Haematological and biochemical analyses
Complete blood counts (CBCs), including erythrocytes, hae-
moglobin, packed cell volume (PCV), platelets, leukocytes, segmented
neutrophils, lymphocytes, monocytes and eosinophils, were determined
in whole blood using the automated laser-based haematology analyser
Advia 120 (Siemens, Healthcare Diagnostics GmbH, Eschborn,
Germany). Concerning biochemical parameters, proteins, aspartate
aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline
phosphatase (ALP), creatine kinase (CK), urea and creatinine levels
were measured in serum using the sequential automatic autoanalyzer
Konelab 30 (Thermo Fisher Scientific, Waltham, USA). Ions such as
calcium, phosphorus, sodium and potassium were assessed in serum
using a Microlyte 3 (Beckman Coulter, Brea, USA). Reference values
were obtained from Ramos-Antón and Ferrer-Mayayo (2007).
2.2.8. Peripheral blood cell stimulation assay and assessment of interferon-
gamma (IFNγ) production
To ensure that blood cells retained the capacity to respond to sti-
mulation and to secrete IFNγ, heparinised blood samples were pro-
cessed within 2 h of collection by mixing 500 μL blood with 500 μL
RPMI 1640 medium (Gibco, Paisley, UK) supplemented with 10% foetal
bovine serum (FBS; Thermo Fisher Scientific, Waltham, USA) and 100X
antibiotic/antimycotic solution (Lonza, Belgium). Blood cells were
cultured in 24-well flat-bottom plates (Thermo Fisher Scientific,
Waltham, USA) in the presence of either soluble N. caninum antigens or
concanavalin A (ConA, Sigma-Aldrich, Madrid, Spain), both at final
concentrations of 5 μg/mL. All experiments were performed in dupli-
cate. Plates were incubated in a 5% CO2/37 °C/100% humidity atmo-
sphere for 24 h. They were then centrifuged at 1000× g for 10min at
4 °C, and cell-free culture supernatants were stored at −80 °C for IFNγ
analyses. IFNγ was detected using a commercial bovine enzyme im-
munoassay kit with a capture monoclonal antibody (MT17.1) showing
cross-reactivity with ovine IFNγ (Mabtech AB, Sweden) as previously
described (Arranz-Solís et al., 2016). Mean optical density (OD) for
each experimental animal was calculated as the mean OD obtained
from each supernatant from the N. caninum antigen-stimulated cells
divided by the mean OD of the same cells incubated with medium alone
(negative control). Afterwards, the mean OD was calculated for each
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experimental group. Supernatant from ConA-stimulated cells was pro-
cessed in a similar way as a positive control for stimulation but was not
included in the subsequent analysis.
2.2.9. Serological analyses: ELISA and IFAT
Neospora caninum-specific IgG antibody levels were measured using
an in-house indirect ELISA. Soluble N. caninum antigen was prepared
according to Álvarez-García et al. (2003). 96-well microtiter plates
(Thermo Fisher Scientific, Waltham, USA) were coated with 100 μL
soluble N. caninum antigen (1 μg/mL in 100mM carbonate buffer pH
9.6) overnight at 4 °C. Subsequently, nonspecific binding was blocked
by adding 300 μL of 3% bovine serum albumin diluted in PBS (pH 7.4)
containing 0.05% Tween 20 (PBS-T). After 2 h incubation at room
temperature (RT), plates were washed three times with PBS-T. Serum
samples were diluted 1:100 in blocking solution, and 100 μL of this
dilution was added to each well and incubated during 1 h at 37 °C. In
each plate, samples of the same positive and negative control sera were
included.
After three washes in PBS-T, 100 μL of horseradish peroxidase-
conjugated protein G (Sigma-Aldrich, Madrid, Spain) diluted 1:2000 in
PBS-T was added and incubated for 1 h at 37 °C. Plates were washed as
above before the addition of 100 μL per well of ABTS substrate (Roche,
Basilea, Switzerland). The reaction was stopped after 14min at RT by
the addition of 100 μL of 0.3 M oxalic acid, and the optical density (OD)
was read at 405 nm (OD405). For each plate, values of the OD were
converted into a relative index percent (RIPC) using the following
formula: RIPC = (OD405 sample – OD405 negative control)/(OD405
positive control–OD405 negative control)× 100. A RIPC value≥ 10
indicates a positive result.
Indirect fluorescent antibody test (IFAT) was used to detect specific
IgG anti-Neospora antibodies in foetal fluids and precolostral sera as
previously described (Álvarez-García et al., 2003). Foetal fluids and
precolostral sera were diluted at two-fold serial dilutions in PBS starting
at 1:8 (for foetal fluids) and 1:50 (for precalostral sera) up to the
endpoint titre. Continuous tachyzoite membrane fluorescence at a titre
≥8 for foetal fluids or ≥50 for precolostral sera was considered a
positive reaction.
2.2.10. Histopathology and lesion scoring
After fixation in formalin for five days, tissue samples were pro-
cessed for histological evaluation. Foetal brain samples were subjected
to measurement of histological lesion characteristics through software-
assisted analysis of digital pictures as previously described (Arranz-Solís
et al., 2015). Briefly, the number (foci/cm2) and average size of lesion
foci (ASF), as well as the total area of the lesion (%LES), were calcu-
lated.
2.2.11. DNA extraction and PCR for parasite detection and quantification
in tissues
Genomic DNA was extracted from 50 to 100mg of maternal and
foetal tissue samples using the commercial Maxwell® 16 Mouse Tail
DNA Purification Kit, developed for the automated Maxwell® 16 System
(Promega, Wisconsin, USA), following the manufacturer's re-
commendations. The concentration of DNA for all samples was de-
termined by spectrophotometry and adjusted to 50–100 ng/μL.
Parasite DNA detection was carried out by a nested-PCR adapted to
a single tube from the internal transcribed spacer (ITS1) region of N.
caninum, using the external primers TgNN1-TgNN2 and internal pri-
mers NP1–NP2 as previously described (Buxton, 1998; Regidor-Cerrillo
et al., 2014). Each reaction was performed in a final volume of 25 μL
with 5 μL of sample DNA.
PCR analysis was performed for six samples of the placentomes in
aborted dams or cotyledons in dams that gave birth and three samples
of foetal brain tissues. Moreover, both reactions without a template and
DNA samples from the uninfected groups (G2, G4 and G6) were in-
cluded in each round of DNA extraction and PCR as negative controls.
Positive PCR controls with N. caninum genomic DNA equivalent to 10, 1
and 0.1 tachyzoites in 100 ng of sheep DNA were also included in each
batch of amplifications. Ten μL aliquots of the PCR products were vi-
sualized under UV light in 1.5% agarose/ethidium bromide gel to detect
the N. caninum-specific 247 bp amplification product.
Placenta and foetal brain samples that had tested positive by nested-
PCR were adjusted to 20 ng DNA/μL and the parasite load was quan-
tified using real-time PCR. Primer pairs from the N. caninum Nc-5 se-
quence (Collantes-Fernández et al., 2002) were used for parasite
quantification, and primers from the β-actin gene (Gutierrez et al.,
2012) were used for the quantification of host DNA. Amplification re-
actions were performed as described by Collantes-Fernández et al.
(2002) with slight modifications in a final volume of 20 μL using Go
Taq® qPCR Master Mix (Promega, Wisconsin, USA), 20 pmol of each
primer and 100 ng of DNA in an ABI 7300 Real Time PCR System
(Applied Biosystems, California, USA). The N. caninum tachyzoite
numbers were calculated by interpolating the average Ct values on two
standard curves: 1) one curve equivalent to 105 to 10−1 tachyzoites
with 10-fold serial dilutions in a solution of ovine genomic DNA, and 2)
a curve of 320, 160, 80, 40, 20, 10, and 5 ng of genomic DNA for ovine
DNA quantification. Parasite numbers in tissue samples (parasite
burden) were expressed as parasite number/mg ovine tissue. Standard
curves for N. caninum and sheep DNA showed an average slope of
−3.45 and −3.33, respectively, and a R2 > 0.99.
2.3. Experiment 2: foetal pharmacokinetics of BKI-1553
2.3.1. Animals and experimental design
Seven pure Churra breed sheep aged 12 months were selected,
oestrus-synchronized and mated as described for Experiment 1.
Pregnancy and foetal viability were confirmed by US on day 40 post-
mating, and three pregnant sheep at 125 ± 9 days of gestation were
selected for the experiment.
2.3.2. Foetal catheterization and clinical monitoring
Pregnant ewes were pre-medicated with flunixin meglumine
(Fluvex, SP Veterinaria, Spain), benzylpencillin (Penilevel, ERN
Laboratorios, Barcelona, Spain) and gentamicin (Gentamicin 60%,
Braun, Barcelona, Spain) following the manufacturer's recommenda-
tions. After 24 h of fasting, pregnant ewes were induced for general
anaesthesia, maintained under inhalation anaesthesia with isofluorane
(Isovet, Braun, Barcelona, Spain) and monitored for physiological
parameters. After hysterotomy and location of the hind limb of one of
the foetuses (Herrera et al., 2012), foetal catheterization of the saphe-
nous vein was performed with the catheter Prowler® Select® Plus, 2,8 F/
150 cm (Cordis, California, USA). The catheter was fixed to the ab-
dominal skin of the pregnant ewes. Pregnant ewes were observed, and
foetal viability was assessed by US monitoring foetal heartbeat and
movements, on a daily basis. At the end of the experiment, pregnant
ewes were sedated and euthanized as described above (subsection
2.2.3).
2.3.3. Drug administration
Upon recovery from anaesthesia, BKI-1553 formulated as described
in subsection 2.2.1 was administered to pregnant sheep subcutaneously
into the right armpit at 10mg/kg bodyweight.
2.3.4. Collection of samples
Pregnant ewes and one of their foetuses were sampled by jugular
venipuncture into 2mL tubes (Aquisel, Barcelona, Spain) containing
lithium heparin as an anticoagulant. Samples were collected prior to
BKI-1553 administration, 1, 2, 4, and 8 h after administration and, if
possible, 24 and 30 h after administration. Heparinised blood samples
were processed as described in subsection 2.2.6 to determine BKI-1553
exposure.
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2.3.5. Statistical analysis
Occurrence of foetal death was analysed by the Kaplan–Meier sur-
vival method. Foetal survival curves were then compared by the Log-
rank (Mantel-Cox) test, and the median foetal survival time, i.e., the
day at which 50% of the foetuses aborted, was calculated. Areas of the
skin lesions, weights of the lambs and antibody responses in foetuses
and lambs were compared using the non-parametric Kruskal–Wallis test
followed by Dunn's test for comparisons between groups, as well as the
Mann–Whitney test for pairwise comparisons. Rectal temperatures were
analysed using Two-way ANOVA of repeated measures testing until 14
days pi and One-way ANOVA test afterwards. Haematological and
biochemical parameters were compared between groups using One-way
ANOVA testing at each time point. Humoral and cellular immune re-
sponses for each experimental group were analysed using Two-way
ANOVA of repeated measures testing until 21 days pi and One-way
ANOVA test afterwards. Differences in Cmax and AUC for infected versus
non-infected and aborted versus non-aborted ewes within the different
treatments were evaluated using the Mann–Whitney test for pairwise
comparisons.
Differences in frequency of PCR detection of parasite DNA were
evaluated using the χ2 or Fisher's exact F-test. Differences in parasite
burdens and histological measurements of lesions were analysed using
the non-parametric Kruskal–Wallis test followed by Dunn's test for
comparisons between groups, as well as the Mann–Whitney test for
pairwise comparisons. Statistical significance for all analyses was es-
tablished at P < 0.05. All statistical analyses were performed using
GraphPad Prism 6.01 software (San Diego, CA, USA).
3. Results
3.1. Experiment 1: plasma concentrations, safety and efficacy of BKI-1553
in a pregnant sheep model of neosporosis
3.1.1. Pharmacokinetics
Cmax for groups treated weekly (G1 and G2) reached
11.7 ± 5.2 μMat 12 h after the first dose administration (35mg/kg)
and 9.0 ± 3.7 μMat 12 h after the second dose (10mg/kg), with
trough plasma concentrations of 4.2 ± 2.9 μM after the first dose and
1.5 ± 1.2 μMat the end of the sampling period, 21 days after the final
dose. Cmax for groups treated at 10mg/kg every 48 h (G3 and G4)
reached 5.7 ± 2.8 μMat 12 h after the first dose and 7.7 ± 4.7 μMat
12 h after the final dose, with trough plasma concentrations of
3.6 ± 2.4 μM after the first dose and 2.2 ± 2.1 μMat the end of the
sampling period, 21 days after the final dose.
No significant differences were observed between the infected and
uninfected animals in groups receiving equivalent treatments for Cmax
or AUCs. For infected ewes receiving weekly treatment (G1), there was
no significant difference between the aborted and not-aborted ewes for
the AUCs or the Cmax for the first or second dose. In infected ewes re-
ceiving treatment every 48 h (G3), there was no significant difference
between the aborted and not-aborted ewes for AUC or Cmax of the first
or final dose.
3.1.2. Clinical observations
In sheep that remained uninfected but received treatment (G2 and
G4), when analysing the recorded rectal temperatures in relation to G6,
a significant increase in G2 was found on day 1 (P < 0.05) and day 2
(P < 0.0001) after treatment, and in G4 on day 1 after treatment
(P < 0.05). Mean rectal temperatures in G2 on day 2 were slightly
above 40 °C (Fig. 1A). Foetuses from G2 and G4 remained alive just
prior to the euthanasia of two dams on days 41 and 47 pi in G2 and of a
dam on day 41 pi in G4. The remaining dams gave birth to 5 healthy
lambs in G2 and 7 healthy lambs and 1 dead lamb due to dystocia in G4
between days 145 and 147 of pregnancy.
Concerning the infected groups, statistically significantly increased
rectal temperatures were found between days 4 (P < 0.05) and 7 pi
(P < 0.0001) in the untreated G5 compared to G6. Furthermore,
compared to G5, rectal temperatures were significantly increased in G1
(P < 0.0001) and G3 (P < 0.001) on day 3 pi (day 1 after treatment),
and a significant decrease was observed in G1 on days 5 (P < 0.0001)
and 6 pi (P < 0.05). Maximum mean rectal temperatures were mea-
sured on day 7 pi in all infected groups (Fig. 1B). No significant dif-
ferences in rectal temperatures were found between aborting and non-
aborting ewes from G1 and G3. From day 14 pi until the end of the
experiment, no changes were found in rectal temperatures.
Dermal nodules at the sites of drug administration were observed
24 h after application of BKI-1553 in all dams from the treated groups,
with areas of 108.8 ± 57.5 cm2 in G1, 102.1 ± 76.1 cm2 in G2,
99.6 ± 67.3 cm2 in G3 and 140.1 ± 66.9 cm2 in G4, without sig-
nificant differences between them. These nodules eventually resolved
over the course of the experiment.
Foetal death was detected by US between 23 and 46 days pi in 5 out
of 8 pregnant ewes in G1 (median day 39 pi), 4 out of 8 pregnant ewes
in G3 (also median day 39 pi) and in all pregnant ewes in G5 (median
day 36 pi). Median foetal survival times were 42, 51 and 36 days for G1,
G3 and G5, respectively. Significant differences were found in the foetal
survival rate between G3 and G5 (P < 0.05). No foetal death was de-
tected in uninfected groups. Dams from the pregnancy control group
(G6) gave birth healthy lambs between days 146 and 150 of pregnancy,
and the foetal survival rate in G6 was significantly different from G5
(P < 0.01) (Fig. 2). The remaining dams from G1 gave birth to 6
healthy and 1 dead lamb on days 145 and 146 of pregnancy, whereas
the remaining dams in G3 gave birth to 7 healthy and 2 dead lambs on
days 142 (premature), 144 and 145 of pregnancy.
Fig. 1. Rectal temperatures of uninfected groups G2, G4 and G6 (A) and infected
groups G1, G3 and G5 and the uninfected/untreated group G6 (B). Each point re-
presents the mean + S.D. for each group. Rectal temperatures represented in the figure
were analysed using Two-way ANOVA of repeated measures. For significant differences,
(*) indicates P < 0.05, (***) indicates P < 0.001 and (****) indicates P < 0.0001.
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Albeit lower, the birthweight of the lambs from G1
(2821.6 ± 360.3 g), G2 (3323 ± 720.6 g) and G4 (2885.8 ± 566.8 g)
did not show statistically significant differences compared to G6
(4037.4 ± 354.7 g), while a significant decrease in the birthweight in
G3 (1845 ± 434.3 g) was found when compared to G6 (P < 0.01) or
to G4 (P < 0.05).
3.1.3. Haematology and biochemistry
Means and standard deviations for each group and reference values
for haematological and biochemical parameters at initial and final time
points are shown in Table 2. Mean values for haematological para-
meters were in the physiological range or showed no significant dif-
ferences when values from the different groups at initial and final time
points were compared. The only exceptions concern the lymphocyte
percentage, which showed a significant increase (P < 0.01) at the final
time point in G5 compared to G3, and the monocyte percentage, which
showed a significant increase (P < 0.05) at the final time point in G3
compared to G1.
Biochemical parameters in the serum such as total proteins were not
different from each other in all groups. Regarding liver function para-
meters, AST showed a significant increase (P < 0.01) in G5 compared
to the other groups at the final time point, but was still within the
normal range. GGT levels were in the physiological range in all groups,
ALP mean values were above the normal range in most cases, and in G2
significantly higher values were noted at initial (P < 0.05) and final
(P < 0.01) time points compared to the other groups. Concerning renal
function parameters, urea levels were normal in all groups, but statis-
tically lower in G1 compared to G3 at the final time point (P < 0.05).
For all groups creatinine showed mean values within a normal range at
initial time points, but these values decreased to below the normal
range at final time points. CK, an early marker of myocardial damage,
was 2-fold higher, thus above the normal physiological range in sheep
initially and at the final time points in all groups. Levels of phosphorus,
sodium and potassium were in the physiological range in all groups
throughout the experiment, whereas calcium levels were slightly above
the physiological range, and statistically elevated levels were noted in
G5 at the final time point compared to the other groups (P < 0.05).
3.1.4. Humoral and cellular immune responses
The N. caninum-specific IgG antibody responses in dams analysed by
ELISA are shown in Fig. 3A. All uninfected control animals in G2, G4
and G6 exhibited basal IgG levels within the reference range
throughout the experimental study. In contrast, compared to the control
groups (G2 + G4 + G6), IgG levels increased significantly from day 14
pi in G5 (P < 0.05), and continued rising until day 21 pi, whereas in
G1 and G3, significantly different IgG levels were only found from day
21 pi (P < 0.0001). On day 21 pi, G3 exhibited significantly lower IgG
levels compared to G1 (P < 0.05) and G5 (P < 0.0001). On day 21 pi,
IgG levels were also compared between aborted ewes and ewes that
gave birth. No significant differences were found in G3, but lower IgG
levels were observed in ewes that gave birth in G1 compared to those
that aborted (P < 0.01). From day 21 pi until foetal death/birth oc-
curred, IgG levels in G1 and G3 remained at similar values, but sig-
nificantly lower values were noted in these two groups in relation to G5
(P < 0.0001) (data not shown).
Aborted foetuses in G1, G3 and G5 were all similarly seropositive,
with titres ranging from 1:32 to 1:1024. Median values of the IFAT
titres were calculated as 1:128 for G1 and G3, whereas G5 showed a
median IFAT titre of 1:256. Precolostral sera collected from lambs born
in G1 and G3 yielded positive titres ranging from 1:200 to 1:6400, with
no significant differences, and median IFAT titres of 1:1600 in both
groups (Additional file 1). Specific IgG responses against parasite an-
tigen were not detected in foetuses/lambs from the three non-infected
control groups (G2, G4 and G6).
IFNγ levels in supernatants of blood cell cultures recovered 24 h
after N. caninum antigen stimulation were significantly increased in
samples from G1, G3 and G5 isolated on day 7 pi (P < 0.0001) and in
cultures from G3 on day 14 pi (P < 0.001). In contrast, blood cell
cultures from non-infected control animals (G2, G4 and G6) showed
IFNγ levels that corresponded to the basal levels recorded prior to in-
oculation throughout the entire experimental study. The increased IFNγ
levels observed in G1, G3 and G5 culture supernatants decreased from
day 21 pi onwards and remained at low levels. Comparisons between
infected groups showed significantly increased IFNγ levels on day 7 pi
in G1 and G3 cultures compared to G5 (P < 0.01) and on day 14 pi in
G3 compared to G1 (P < 0.05) (Fig. 3B). When IFNγ values of stimu-
lated cultures from aborting and non-aborting ewes were compared, no
significant differences on day 7 pi were found in G1, but in G3 the
cultures from aborting ewes produced significantly more IFNγ com-
pared to cultures from non-aborting ewes (P < 0.01).
3.1.5. Pathology and lesion quantification
No histopathological lesions were found in the uninfected and
treated groups (G2 and G4) or in the uninfected and untreated group
(G6) (Fig. 4A–C). Foci of necrosis with variable degrees of infiltration of
inflammatory cells, primarily lymphocytes and macrophages, were
found in all placentomes from all aborted ewes in infected groups
(Fig. 4B). Cotyledons from ewes that gave birth were too autolytic to
permit proper histological evaluation. In foetal brains from infected
sheep, lesions were found in 79%, 83% and 92% in G1, G3 and G5,
respectively. In aborted foetuses from G1 and G3, 100% of foetal brains
exhibited lesions, whereas 57% and 75% of foetal brains from lambs
born in G1 in G3 showed lesions, respectively. Histological lesions were
characterized by necrotic glial foci with random distribution in the
neuropile (Fig. 4D). The number of foci, average area of the lesions, and
the percentages of damaged area showed no significant differences
between infected groups (Additional file 1). However, within G1 and
G3, when comparing the lesions found in aborted foetuses with those
found in lambs, significant differences were found regarding the
number of foci and percentage of damaged area. In G1, foetal brain
from lambs born showed lower numbers of foci (P < 0.05) and per-
centages of damaged area (P < 0.01) compared to aborted foetuses.
Similarly, foetal brains from lambs born in G3 showed lower numbers
of foci (P < 0.01) and percentages of damaged area (P < 0.05) com-
pared to aborted foetuses (Fig. 5). No differences in those parameters
were seen when aborted foetuses from different groups were compared,
and when lambs from different groups were analysed.
3.1.6. Parasite detection and burden in placental tissues and foetal brain
Neospora DNA was detected in placentomes or cotyledons from all
ewes in the three infected groups, with 100% positive samples of the
placentomes (30/30) or cotyledons (18/18) in G1, 96% positive
Fig. 2. Kaplan–Meier survival curves for foetuses in the infected groups G1 and G3
treated with BKI-1553, infected group G5, and the non-infected groups. Each point
represents the percentage of surviving animals at that day, and downward steps corre-
spond with observed deaths. Foetal survival curves were compared by the Log-rank
(Mantel-Cox) test. For significant differences between foetal survival curves of infected
groups, (*) indicates P < 0.05.
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samples of the placentomes (23/24) and 100% positive samples of the
cotyledons (24/24) in G3 and 100% positive samples of the pla-
centomes (48/48) in G5, with no statistical significances between them.
The mean parasite burden (measured as the number of tachyzoites per
mg of tissue) in placentomes from aborting ewes in G3 was higher
compared to G5 (P < 0.01), and no significant differences were found
compared to G1 (Fig. 6A). Likewise, parasite burdens in cotyledons
from ewes that gave birth were significantly lower in G1 than G3
(P < 0.0001) (Fig. 6B).
A significantly higher percentage of Neospora positive foetal brains
was detected in G5 (37/39) compared to G1 (30/42) (P < 0.05) and
G3 (27/39) (P < 0.05) (Additional file 1). In G1 and G3, no significant
differences were found for the percentage of detection in foetal brains
between aborted foetuses and lambs born. In aborted foetuses of G1, a
significantly higher number of foetal brain samples (19/21) was Neos-
pora PCR positive compared to samples obtained from lambs born (11/
21) (P < 0.05). However, no significant differences were found when
comparing aborted foetuses (10/12) and lambs born (17/27) in G3.
Furthermore, the overall parasite burden in the brains of aborted foe-
tuses in G5 was significantly higher compared to G3 (P < 0.01)
(Fig. 6C) (Additional file 1). When comparing brain parasite burdens
between infected groups, no significant differences were found in foetal
brains between aborted foetuses or between lambs born. However,
aborted foetuses in G5 showed higher brain parasite loads than lambs
born from G1 (P < 0.0001) and G3 (P < 0.001). Additionally, sig-
nificant differences were observed between aborted foetuses and lambs
born in G1 when comparing brain parasite burdens (P < 0.0001). As
expected, all placental and foetal samples from G2, G4 and G6 were
negative.
3.2. Experiment 2: BKI-1553 plasma levels in foetal blood
The Cmax was 5.9 ± 3.2 μM for pregnant ewes and 1.6 ± 0.2 μM
for foetuses, resulting in a ratio between foetuses and pregnant ewes of
0.27 ± 0.10 (Fig. 7). The AUC was 2608 ± 1469 μM*min for preg-
nant ewes and 603 ± 61 μM*min for foetuses, resulting in a ratio
between foetuses and pregnant ewes of 0.23 ± 0.12.
4. Discussion
This study reports on BKI-1553 drug levels in plasma of pregnant
sheep and foetuses, and the safety and anti-parasitic efficacy of BKI-
1553 treatment in a pregnant sheep model of neosporosis. The efficacy
was assessed with respect to the clinical course of disease, immune
responses, lesion development and parasite detection and load in pla-
cental tissues and foetal brains. To our knowledge, this is the first
evaluation of a therapeutic drug candidate in a pregnant ruminant
model of neosporosis.
Compared to previously developed BKIs, BKI-1553 has shown
greatly improved bioavailability based on mouse pharmacokinetic data,
with systemic levels> 30-fold higher than BKI-1294 (Vidadala et al.,
2016). Consequently, BKI-1553 has been tested in calves, resulting in
successful systemic exposure after a single dose with maximum con-
centrations 12 h after administration (Schaefer et al., 2016; Vidadala
et al., 2016), or multiple-doses with steady state plasma concentrations
25-fold higher than BKI-1294 (Schaefer et al., 2016). Here, BKI-1553
demonstrated excellent exposure in pregnant ewes after multiple sub-
cutaneous applications. Maximum concentrations> 5 μM were reached
at 12 h after administration. Trough concentrations of approximately
4 μM were found, with> 1 μM in most of the pregnant ewes until the
end of the sampling period. Because neosporosis greatly affects the
foetus, foetal blood levels of BKI-1553 was evaluated in pregnant ewes.
BKI-1553 application resulted in foetal plasma concentrations of
1.6 ± 0.2 μM, which corresponded to approximately 20–30% of the
systemic exposure in pregnant ewes over 24–30 h post dose. Different
sheep breeds were used in experiments 1 and 2. However, since very
similar Cmax were found in both experiments when the drug was applied
at 10mg/kg, it is conceivable that potential differences associated with
the use of different sheep breeds in the two experiments can be dis-
carded. Previous studies addressing the in vitro efficacy of BKI-1553
against N. caninum reported a half-maximal inhibitory concentration
(IC50) of 0.18 ± 0.03 μM (Müller et al., 2017a). Plasma concentrations
of BKI-1553 in pregnant ewes and their foetuses were higher than the
IC50 for N. caninum, perhaps indicating adequate exposure that could
translate into good efficacy in the pregnant sheep model of neosporosis.
We did not find a significant association between individual levels of
BKI-1553 and the outcome of foetal infection. However, the number of
animals used here are small, and the variability in outcome may have
been more affected by the actual drug concentrations in target tissues,
which were not assessed. The concentration of free BKI-1553 in target
tissues probably determines efficacy, and>90% of BKI-1553 is plasma
protein bound, suggesting the levels of free drug may not have been
completely adequate to achieve 100% efficacy (Vidadala et al., 2016).
In addition, some target tissues, such as foetal brain, may not have
obtained sufficient drug levels to achieve complete efficacy (see below).
BKI-1553 treatment in mice did not cause any adverse side effects
leading to toxicity, and complete blood counts and serum biochemical
profiles were within normal ranges, suggesting that the compound was
safe. However, although no gross abnormalities upon necropsy were
found, histological examination revealed inflammation in the spleen
and liver in several treated mice (Vidadala et al., 2016). When BKI-
1553 was applied to pregnant mice daily at 20 mg/kg bodyweight for 5
Fig. 3. IgG response in sera (A) and IFNγ in supernatants of peripheral blood cell
cultures (B). Values from infected (G1, G3 and G5) and uninfected (G2+G4+G6)
pregnant ewes are represented. Each point represents the mean + S.D. at the different
sampling times for each group. Data beyond day 21 pi are not shown, since several an-
imals did not maintain pregnancy and were therefore sacrificed. Sera levels of total IgG
antibodies against N. caninum are expressed as a relative index percent (RIPC), according
to the formula: RIPC = (OD405 sample – OD405 negative control)/(OD405 positive
control – OD405 negative control) × 100. Concentrations of IFNγ are expressed in pg/
mL. Humoral and cellular immune responses represented in the figure were analysed
using two-way ANOVA of repeated measures. For significant differences between infected
groups, (*) indicates P < 0.05, (**) indicates P < 0.01 and (****) indicates
P < 0.0001.
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days, it caused high neonatal mortality; this did not occur after ad-
ministration at 20mg/kg bodyweight 3 times with one-day intervals
after each drug treatment (Müller et al., 2017a). Likewise, BKI-1553
was safe in calves, with no toxicity observed after administration
(Schaefer et al., 2016; Vidadala et al., 2016). In the present study,
dermal nodules were found 24 h after drug application at the sites of
administration in all treated dams. Similar dermal nodules were found
after vehicle (70% Tween 80 and 30% Ethanol 96°) administration in
sheep (data not shown), indicating that the dermal nodules could be
formed due to the vehicle. A formulation comprised of 7% Tween 80,
3% ethanol 96° and 90% normal saline has been already used in mice
for oral administration of BKI-1294 (Ojo et al., 2013) and in rats for oral
and intravenous administration of antimalarial drugs (Van Voorhis
et al., 2007). In this study, higher percentage of Tween 80 and ethanol
96° was chosen as drug vehicle to achieve drug concentration that
would allow the volume be administered subcutaneously. The much
higher percentages of Tween 80 and Ethanol 96° could have triggered
the appearance of mild dermal nodules. Concerning systemic side ef-
fects, non-infected pregnant ewes treated with BKI-1553 (G2 and G4)
exhibited an increase in rectal temperatures on days 1 and 2 post-
treatment start in G2 and on day 1 in G4; there were no associated
abortions, and dams gave birth to healthy lambs without significant
decreased birthweights. Furthermore, no microscopic lesions were
found in placental and foetal tissues examined from these groups.
The haematological assessments in G2 and G4 showed no alterations
in red and white blood cell counts (RBCs and WBCs, respectively). In
contrast, in the infected groups, a minor monocytosis was found in G3,
and an increase in lymphocyte percentages (still within the normal
range) was detected in G5 at the final time point. Thus, due to normal
monocyte percentages in G5 after infection, the minor monocytosis
found in G3 could have been derived from dermal nodules arising after
7 BKI-1553 administrations over short intervals. Additionally, it was
suggested that monocyte levels increase during the recovery period
during inflammation (Weiss and Perman, 1992). Biochemical para-
meters in G2 and G4 to evaluate liver function, such as GGT and AST,
were consistently in the physiological range at all time points. ALT
displayed irrelevant higher values in G2; increased concentrations
normally appear during late pregnancy in sheep (Yokus et al., 2006).
The apparent lack of liver toxicity is important because liver metabo-
lism is hypothesized to be predominant for BKI-1294 in mice (Ojo et al.,
2013) and might also occur for BKI-1553, since it is also based on the
naphthalinyl-pyrazolopyrimidine scaffold. Despite only 1% of BKI-1294
being excreted in urine (Ojo et al., 2013), renal function parameters are
essential for toxicity evaluation. In this study, no remarkable abnorm-
alities were found for urea and creatinine values in G2 and G4. CK
showed levels above the physiological range, although increased con-
centrations can typically appear in late pregnancy (Yokus et al., 2006).
CK and AST values have been previously described as valuable for in-
vestigating cardiotoxicity of drugs in lambs (Ekici and Isik, 2011). In
contrast to BKI-1294, which was shown to be a potent human ether-a-
go-go-related gene (hERG) inhibitor, BKI-1553 does not have a hERG
liability (Vidadala et al., 2016). Myocardial damage in sheep was not
identified, since the corresponding markers AST and CK were not al-
tered in G2 and G4 after BKI-1553 administration. No notable disorders
related to minerals were observed after BKI-1553 administration, and
the observed calcium levels slightly above the basal range may have
been due to calcium regulation disruption associated with foetal de-
mands in late pregnancy (Kovacs and Kronenberg, 1997).
Initiation of BKI-1553 treatment 48 h after infection was scheduled
based on experience with BKI therapy in murine neosporosis (Winzer
et al., 2015; Müller et al., 2017a) and toxoplasmosis models (Doggett
et al., 2014; Huang et al., 2015; Müller et al., 2017b). The pregnant
Fig. 4. Hematoxylin and eosin staining. A) Interdigitate area of the placentome of an uninfected sheep with no evident lesion. B) Foci of necrosis and scant inflammatory infiltration at
the interdigitated area of the placentome of an infected sheep. C) Foetal brain from an uninfected sheep with no evident lesion. D) Glial foci with central necrosis at the foetal brain from
an infected sheep. Bar: 200 μm.
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Fig. 5. Box-plots showing number of lesions (A), average size of focus (B) and lesion
rates (C) in foetal brains from G1 and G3. Graphs represent the median percentage, the
lower and upper quartiles (boxes) and minimum and maximum values (whiskers).
Histological measurements of lesions were analysed using the non-parametric
Kruskal–Wallis test followed by Dunn's test for comparisons between groups, as well as
the Mann–Whitney test for pairwise comparisons. For significant differences between
infected and treated groups, (*) indicates P < 0.05 and (**) indicates P < 0.01.
Fig. 6. Dot-plot graphs of N. caninum burdens in placentomes (A), cotyledons (B)
and foetal brain (C) from G1, G3 and G5. Each dot represents individual values of
parasite burden (number of parasites per mg of host tissue), and medians are represented
as horizontal lines. Considering that the N. caninum detection limit by real-time PCR is 0.1
parasites, negative samples (0 parasites) were represented on the log scale as<0.1 (i.e.,
10−2). Parasite burdens were analysed using the non-parametric Kruskal–Wallis test
followed by Dunn's test for comparisons between groups, as well as the Mann–Whitney
test for pairwise comparisons. For significant differences between infected groups in each
tissue, (**) indicates P < 0.01 and (****) indicates P < 0.0001.
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sheep model of neosporosis with infection on day 90 of pregnancy had
been standardized to the extent that all pregnant ewes aborted between
34 and 48 days pi (Arranz-Solís et al., 2015). In this experiment,
pregnant ewes from G5 displayed the same pattern, although a different
breed was used. Clinical observations in the BKI-1553 treated groups
revealed a partial protection against abortion, as 37 and 50 percent of
the pregnant ewes gave birth in G1 and G3 respectively, with statisti-
cally improved foetal survival rates and median foetal survival times in
G3. However, lambs in group G3 exhibited lower birthweights com-
pared to uninfected lambs, regardless of treatment, which indicates that
infection, but not the treatment, impacted on the weight in this group.
Rectal temperatures in pregnant ewes in G5 increased from day 4 to day
7 pi, likely as a consequence of tachyzoite multiplication and the first
cycles of parasite replication in host tissues, similar to previously re-
ported results in cattle and goats experimentally infected with the Nc-
Spain7 isolate (Regidor-Cerrillo et al., 2014; Porto et al., 2016). The
rectal temperatures from pregnant ewes in G1 were lower than G5 on
days 5 and 6 pi, suggesting that the drug had an impact on parasite
replication. A decrease in rectal temperatures has also been described in
experiments testing toltrazuril against neosporosis in calves (Kritzner
et al., 2002) and monensin (Buxton et al., 1988) or decoquinate (Buxton
et al., 1996) against toxoplasmosis in pregnant ewes. Additionally,
since AST typically increases after T. gondii infection, indicating liver
injury (Yeo et al., 2016), the increased AST in G5 and not in G1 and G3
at the final time point might indicate that treated pregnant ewes ex-
erted better control of N. caninum infection.
Analysis of the peripheral immune responses in pregnant ewes at
different time points demonstrated an increase in IFNγ release in sti-
mulated peripheral blood cultures from G5 obtained at day 7 pi,
showing similar kinetics to IFNγ in sera (Arranz-Solís et al., 2016).
Several reports have shown that a Th1-biased immune response against
N. caninum is required to control tachyzoite proliferation (Entrican,
2002; Innes, 2007). IFNγ levels were higher on day 7 pi in G1 and G3
and on day 14 pi in G3, compared to G5. In vitro studies showed that
BKI-1553 exhibited parasitostatic rather than parasiticidal effects, and
induced the formation of intracellular multinucleated complexes com-
posed of multiple pre-zoites unable to separate and form tachyzoites,
but remaining viable for extended periods of time (Müller et al.,
2017a). These multinucleated complexes exhibit increased tachyzoite
specific antigen1 (SAG1) expression, and also increased expression of
the bradyzoite marker BAG1, with an overall heavily distorted parasite
ultrastructure (Winzer et al., 2015; Müller et al., 2017a). If such com-
plexes are also formed in vivo, they are unlikely to evade immune re-
sponses, but would be increasingly exposed to antigen-presenting cells,
which would then result in higher IFNγ levels in treated animals.
Likewise, increased IFNγ levels in G3 on day 14 pi might be caused by
extended BKI-1553 administration in this group, although IFNγ levels
were not elevated in the corresponding uninfected group (G4). The
increased levels of IFNγ in G1 and G3 might have led to greater initial
control of parasitaemia at the peripheral level, diminishing the numbers
of parasites reaching and invading the placenta (Entrican, 2002; Innes,
2007).
Concerning humoral immune responses, the levels of IgG started to
increase in G5 on day 14 pi, which was in accordance to previously
described results (Arranz-Solís et al., 2016). However, antibody re-
sponses in the treated groups were delayed. As explained above, lym-
phocyte counts showed an increase in G5 at day 13 pi, and it is likely
that this also includes B cells. On day 21 pi, significantly decreased IgG
levels were found in G1 and G3, but G3 showed lower IgG values than
the other two infected groups G1 and G5. Similarly decreased antibody
responses have been previously reported during treatments of N. ca-
ninum infected calves with toltrazuril (Kritzner et al., 2002) and mon-
ensin (Buxton et al., 1988) or decoquinate (Buxton et al., 1996) treat-
ment trials against toxoplasmosis in pregnant ewes. In treated groups,
the delay at day 14 pi and lower antibody responses from day 21 pi
onwards may have been due to higher IFNγ levels in the early stage of
infection, as previously described (López-Gatius et al., 2007) under
natural conditions. Likewise, longer IFNγ responses in G3 could con-
tribute to reduced IgG levels on day 21 in this group. In contrast, on day
21 pi, IgG levels from pregnant ewes that aborted in G1 were higher
than those that gave birth, suggesting that higher antibody responses
occurred in animals that aborted their foetuses, as previously described
(Almería et al., 2016).
At approximately mid-gestation in pregnant ewes, the foetal im-
mune system is undergoing development, according to specific anti-
bodies detected in foetal fluids (Arranz-Solís et al., 2015). While BKI-
1553 treatment had a beneficial impact on offspring survival, the drug
did not prevent transplacental transmission. All foetuses/lambs were
seropositive as assessed by IFAT. However, lower median IFAT titres
were found in aborted foetuses from the treated groups G1 and G3,
which is indicative for decreased antigen stimulation and thus en-
hanced control of N. caninum infection. To quantify the efficacy of BKI-
1553 against transplacental transmission of N. caninum, microscopic
lesions, detection and burden of N. caninum in placental tissues and
foetal brains were investigated. In placental tissues N. caninum was
widely detected in infected groups, as well as lesions in all placentomes
from aborting ewes. In foetal brains, known as a predilection site for N.
caninum (Collantes-Fernández et al., 2006), parasites were less abun-
dant, and the percentage of foetal brains with histological lesions was
reduced in the treated groups. This is likely due to the efficacious BKI-
1553 concentrations present in the foetuses. These results are consistent
with those from a pregnant mouse model of neosporosis, in which re-
duced transplacental transmission to offspring was accomplished
(Müller et al., 2017a). In the treated groups, histopathological analysis
revealed a lower percentage of foetal brains with lesions, lower num-
bers of foci, and lower percentage of damaged areas in lambs that were
born compared to aborted foetuses, which is in accordance to pre-
viously described studies (Macaldowie et al., 2004). Additionally, the
parasite burden in foetal brains was reduced in G3 but not in G1, and in
G1, but not G3, a higher parasite load was found in aborted foetuses
compared to lambs born. Thus, the treatment undergone in G3 ap-
peared to show higher efficacy in terms of controlling brain infection in
the offspring. In both G1 and G3, cerebral parasite loads in lambs born
were found to be lower compared to cerebral parasite loads in aborted
foetuses in G5. Central nervous system (CNS) penetration by BKI-1553
could possibly explain why, despite a lack of difference in systemic
exposures, some foetuses aborted and others were protected. CNS pe-
netration of BKI-1553 was previously found to be approximately 33%
compared to plasma exposure in mice (Vidadala et al., 2016). If this is
similar in sheep, then BKI-1553 concentrations in foetal brains would
be≤ 2 fold above the N. canimum IC50 level at the troughs for all dose
concentrations. Such rather low concentrations would most likely only
offer incomplete protection at this infection site in foetuses.
In conclusion, BKI-1553 treatment in N. caninum infected dams re-
sulted in decreased rectal temperature upon infection, triggered an
Fig. 7. Plasma concentrations of BKI-1553 in pregnant ewes and foetuses after
single 10mg/kg subcutaneous dose. Each point represents the mean + S.D. at the
different sampling times for pregnant ewes and foetuses.
R. Sánchez-Sánchez et al. IJP: Drugs and Drug Resistance 8 (2018) 112–124
122
increase in peripheral IFNγ levels and a reduction in IgG responses, and
achieved a reduced abortion rate due to neosporosis. In foetuses, BKI-
1553 treatment did not prevent vertical transmission, but partially al-
leviated the effects of infection, by reducing lesions, parasite presence
and parasite loads in foetal brains. In the light of these findings, BKI-
1553 exhibits an excellent systemic exposure in pregnant ewes and
their foetuses, a tolerable safety profile and confers partial protection
against abortion and foetal dissemination of the parasite in a pregnant
sheep model of neosporosis. However, the reduction in terms of parasite
detection in foetal brain was only 25%, which indicates a rather low
efficacy of this particular treatment regime. Further studies are neces-
sary to explore efficacy of BKI-1553, by applying alternative formula-
tions and using other routes of administration, drug dosages and dosing
regimes. In addition, other members of the BKI class of compounds
under development could be tested in the near future against ruminant
neosporosis.
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